Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Latest videos

PlayWhat’s new on the horizon for lipoprotein(a) therapies?
Henry Ginsberg What’s new on the horizon for lipoprotein(a) therapies?
PlayShould ACS patients start a PCSK9 inhibitor in hospital?
Steve Nicholls Should ACS patients start a PCSK9 inhibitor in hospital?
PlayAPOLLO trial with SLN360
Steve Nicholls APOLLO trial with SLN360
PlayWhat can we learn from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration registry?
Tycho Tromp What can we learn from the Homozygous Familial Hypercholesterolaemia International Clinical Collaboration registry?

« Back to videos